Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment

Schmoll, Hans Joachim; Aapro, Matti; Poli-Bigelli, S.; Kim, H.-K.; Park, K.; Jordan, Karin; Pawel, Joachim von; Giezek, Hilde; Ahmed, Tuli; Chan, Christina Y.

doi:10.1093/annonc/mdl019

Cited by 219 publications

(172 citation statements)

References 17 publications

Supporting

Mentioning

149

Contrasting

Unclassified

Order By: Relevance

“…Those studies evaluated patients who were receiving chemotherapy for breast cancer, lung cancer, ovarian cancer, and head and neck cancer. [4][5][6][7] The National Comprehensive Cancer Network (NCCN) guidelines for antiemesis prophylaxis currently include the use of both a 5-HT 3 antagonist for high-emetogenic-risk (HER) regimens and an SPA for moderate-emetogenic-risk (MER) regimens. 8 However, barriers to effective antiemesis prophylaxis have been noted, the most significant of which may be cost.…”

Section: Introductionmentioning

confidence: 99%

Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer

Gomez

Liao

Giordano

et al. 2012

Cancer

View full text Add to dashboard Cite

BACKGROUND: Nausea and vomiting (N/V) during chemotherapy can have profound clinical and economic consequences. Effective antiemetic agents are available for prophylaxis, but barriers may prevent their use. For this population-based study, the authors assessed the rates of antiemetic prophylaxis use, and predictors of such use, among patients who were receiving platinum-based chemotherapy for lung cancer between 2001 and 2007. METHODS: The authors searched the Texas Cancer Registry-Medicare-linked database for individuals aged >65 years who received platinum-based chemotherapy within 12 months after a first diagnosis of lung cancer from 2001 to 2007; and all patients had continuous Medicare Part A and Part B coverage for the same period. Adherence to recommended regimens for N/V prophylaxis (established by the National Comprehensive Cancer Network) was scored as a binary variable (adherent vs nonadherent) and was calculated as the percentages of treated patients receiving each recommended agent within 1 day of beginning chemotherapy. Logistic regression with stepwise selection was used to examine whether patient characteristics influenced adherence. RESULTS: Of 4566 selected patients, adherence rates for the receipt of serotonin antagonists (eg, ondansetron) with dexamethasone were 60% to 90% regardless of whether the chemotherapy agent was considered moderately or highly emetogenic. The receipt of substance-P antagonists was much less common (<10%) during any period. On multivariate logistic regression modeling, variables that predicted adherence were older age, white race, higher median income, and concurrent radiation therapy. CONCLUSIONS: Recommended use of antiemetics for prophylaxis, especially substance-P antagonists, during chemotherapy for lung cancer is suboptimal. Factors that were correlated with adherence suggest socioeconomic barriers in the community. Cancer INTRODUCTIONNausea and vomiting during chemotherapy can have profound clinical and economic consequences, including malaise, dehydration, electrolyte abnormalities, weight loss, feeding tube placement, hospitalization, and death. These symptoms also can lead to decreased treatment adherence and, hence, inadequate therapy. In 1 population-based analysis, Burke et al studied the clinical impact of chemotherapy-induced nausea and vomiting (CINV) from agents considered at high or moderate risk of inducing emesis and observed that, after the first cycle of chemotherapy, the risk of resultant inpatient admissions, emergency room visits, or outpatient hospital visits was 18%. Those authors also observed that the cost of treating patients who experienced CINV after the first cycle could reach $9578 per patient. They concluded that visits for CINV during the first cycle of chemotherapy were both common and costly and that strategies to reduce the incidence of CINV could reduce health care use and cost.

show abstract

Section: Introductionmentioning

confidence: 99%

Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer

Gomez

Liao

Giordano

et al. 2012

Cancer

View full text Add to dashboard Cite

show abstract

“…[44][45][46][47] An important finding was that the single oral dose of casopitant 150 mg proved to be as efficient as the threeday regimens, and all regimens seemed to protect patients against emesis in the same order as seen in previous studies with aprepitant. [6][7][8][9] No unexpected side effects have been described in phase II-III studies (only abstract publications available). Of particular interest is the low degree of neutropenia with or without fever.…”

Section: Dovepressmentioning

confidence: 99%

“…Even a significant reduction in delayed emesis was demonstrated. [6][7][8][9] In 2003, the first NK 1 receptor antagonist, aprepitant, …”

Section: Introductionmentioning

confidence: 99%

Casopitant: a novel NK1-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting

Ruhlmann¹,

Herrstedt²

2009

TCRM

View full text Add to dashboard Cite

Chemotherapy-induced nausea and vomiting (CINV) are among the most feared and distressing symptoms experienced by patients with cancer. The knowledge of the pathogenesis and neuropharmacology of CINV has expanded enormously over the last decades, the most significant discoveries being the role of 5-hydroxytryptamine (5-HT) 3 -and neurokinin (NK) 1 receptors in the emetic reflex arch. This has led to the development of two new classes of antiemetics acting as highly selective antagonists at one of these receptors. These drugs have had a huge impact in the protection from chemotherapy-induced vomiting, whereas the effect on nausea seems to be limited. The first NK 1 receptor antagonist, aprepitant, became clinically available in 2003, and casopitant, the second in this class of antiemetics, has now completed phase III trials. This review delineates the properties and clinical use of casopitant in the prevention of CINV.

show abstract

“…4 In the 1990s, the introduction of serotonin receptor antagonists (5-HT 3 RAs) improved the management of acute CINV associated with both moderately and highly emetogenic CT, [5][6][7][8] but no improvement was shown in the prophylaxis of delayed CINV. [9][10][11][12] The second-generation 5-HT 3 RA, namely palonosetron, and the neurokinin receptor antagonist, aprepitant, have improved not only the prevention of acute CINV, but also the prophylaxis of delayed CINV [13][14][15][16][17][18][19] after both moderately and highly emetogenic CT. However, control of delayed CINV is still an open problem, especially in patients undergoing multiple-day [20][21][22][23] or high-dose (HD)-CT. [24][25][26][27] Two recent studies 28,29 have shown the efficacy and safety of palonosetron plus dexamethasone in preventing CINV during and after multiple-day CT.…”

Section: Introductionmentioning

confidence: 99%

Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT

Musso

Scalone

Crescimanno

et al. 2009

Bone Marrow Transplant

View full text Add to dashboard Cite

The aim of this study was to determine the efficacy of palonosetron combined with dexamethasone in prevention of chemotherapy (CT)-induced nausea and vomiting (CINV) in patients receiving high-dose (HD)-CT with auto-SCT, and the efficacy of a second dose of palonosetron in treating breakthrough emesis. One hundred thirty-four patients treated with HD-CT and auto-SCT for hematologic malignancies received palonosetron as prophylaxis for CINV on the first day of conditioning; patients were also administered dexamethasone throughout the entire period of conditioning. If breakthrough emesis occurred, a second dose of palonosetron was administered at 72 h after the first administration. Complete response and complete protection were observed in 36 and 26% of patients, respectively. One-half of the patients, re-treated with palonosetron for breakthrough emesis, were successfully rescued. Treatment with palonosetron plus dexamethasone seems to be encouraging in terms of prophylaxis of CINV and treatment of breakthrough emesis in the setting of HD-CT.

show abstract

Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment

Cited by 219 publications

References 17 publications

Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer

Adherence to national guidelines for antiemesis prophylaxis in patients undergoing chemotherapy for lung cancer

Casopitant: a novel NK1-receptor antagonist in the prevention of chemotherapy-induced nausea and vomiting

Palonosetron and dexamethasone for prevention of nausea and vomiting in patients receiving high-dose chemotherapy with auto-SCT

Contact Info

Product

Resources

About